Natural history of Becker muscular dystrophy: DMD gene mutations predict clinical severity
Domenico Gorgoglione,Daniele Sabbatini,Pietro Riguzzi,Giuliana Capece,Marika Pane,Serenella Servidei,Marta Briganti,Cristina Sancricca,Fabio Bruschi,Anna Ardissone,Riccardo Masson,Annamaria Gallone,Lorenzo Maggi,Esther Picillo,Luisa Politano,Angela Petrosino,Sara Vianello,Martina Penzo,Matteo Villa,Maria Sframeli,Cosimo Allegra,Andrea Barp,Alessandra Di Bari,Francesca Salmin,Emilio Albamonte,Giovanni Colacicco,Chiara Panicucci,Monica Traverso,Concetta Palermo,Alberto Lerario,Daniele Velardo,Maria G D'Angelo,Angela Berardinelli,Alice Gardani,Roberta Nicotra,Stefano Parravicini,Gabriele Siciliano,Giulia Ricci,Francesca Torri,Giulio Gadaleta,Guido Urbano,Enrica Rolle,Federica Ricci,Adele D'Amico,Michela Catteruccia,Antonella Pini,Melania Giannotta,Roberta Battini,Gemma Marinella,Stefano C Previtali,Alberto A Zambon,Alessandra Ferlini,Fernanda Fortunato,Francesca Magri,Tiziana E Mongini,Valeria A Sansone,Claudio Bruno,Sonia Messina,Vincenzo Nigro,Isabella Moroni,Eugenio Mercuri,Luca Bello,Elena Pegoraro
DOI: https://doi.org/10.1093/brain/awae358
IF: 14.5
2024-11-06
Brain
Abstract:Becker muscular dystrophy (BMD) is an X-linked neuromuscular disease due to mutations in the DMD gene, leading to a deficient and less functional dystrophin mainly in skeletal and cardiac muscle. Understanding the natural history of BMD is crucial for optimizing patient care and developing targeted treatments. Retrospective data were collected from 943 patients diagnosed with BMD based on a combination of clinical, biochemical and genetic criteria followed by 17 Italian neuromuscular centers. Patients' demographics, main signs and symptoms at BMD onset, neuropsychiatric comorbidities, age at loss of ambulation (LoA), cardiac left ventricular ejection fraction (LVEF), pulmonary forced vital capacity (FVC), and DMD mutations were collected. Disease milestones were analysed in specific DMD mutational groups. the median age at the last assessment was 26.0 (16.6-41.9) years, with a median age at diagnosis of 7.5 (4.0-14.0) years. In 55% of patients, the diagnosis was prompted by the incidental finding of hyperCKemia. At the last assessment, 13.5% of patients had lost the ability to walk at a median age estimated by Kaplan-Meier analysis of 69 years. Thirty percent of patients exhibited left ventricular impairment and 2.7% respiratory involvement. Ten percent of patients carried out-of-frame mutations, 4% nonsense mutations, and 86% in-frame deletions/duplications. The subset of in-frame deletions was further classified based on the specific mutations. Patients carrying del45-49 compared to del45-47 were associated with an earlier LoA ( P =1×10 −4 ), where patients with del45-55 ( P =.005), del48 ( P =.02), and del48-49 ( P =.02) correlated with a later LoA compared to del45-47. del45-55 ( P =.002) and del48 ( P =.003) were significantly associated with decreased odds of developing a pathological LVEF% compared to del45-47. Our results contribute to the better understanding of the natural history of BMD and capture precious data in the era of the emerging therapies. The knowledge of the specific DMD mutation may help to define a prognosis in a subset of BMD patients and will serve as a model for the design of future therapies.
neurosciences,clinical neurology